| Autor: |
Salcin H; Basic Oncology Department, Ege University Health Science Institute, Izmir, Turkey.; Medical Biology Department, Ege University Medical School, Izmir, Turkey., Goker Bagca B; Medical Biology Department, Aydin Adnan Menderes University Medical School, Aydin, Turkey., Alcitepe I; Medical Biology Department, Ege University Medical School, Izmir, Turkey., Biray Avci C; Medical Biology Department, Ege University Medical School, Izmir, Turkey., Aslan R; Addiction Toxicology Department, Ege University Institute of Substance Abuse, Toxicology and Pharmaceutical Sciences, Izmir, Turkey., Annette Akgur S; Addiction Toxicology Department, Ege University Institute of Substance Abuse, Toxicology and Pharmaceutical Sciences, Izmir, Turkey., Tezcanli Kaymaz B; Medical Biology Department, Ege University Medical School, Izmir, Turkey. |
| Abstrakt: |
The popularity and usage of synthetic cannabinoids (SCs) are increasing due to their easy accessibility and psychoactive effects worldwide. Studies on cannabinoids on leukemic stem cells (LSC) and hematopoietic stem cells (HSCs), which are the precursors of leukemia cells, generally depend on the natural cannabinoid delta-9-THC. As there is only a limited number of studies focusing on the results of SC applications, the reflections upon LSCs have to be clarified. In this study, biological responses and antileukemic effects of JWH-018-one of the first produced and widely used SCs-were evaluated upon leukemia cells. Whether JWH-018 exhibited a preventive effect on both leukemic and HSCs was evaluated by presenting a therapeutic approach for the first time in the literature. Cells were analyzed in case of cell proliferation, apoptosis, and transcriptional expression profiling of some significant JAK/STAT and AKT/mTOR pathways, apoptotic, cell cycle regulation, and epigenetic chromatin remodeling-related genes following JWH-018 treatment. In conclusion, however, further studies are still needed upon both HSCs and LSCs to illuminate the effects of SCs on leukemogenesis on chronic myeloid leukemia (CML) more clearly; we consider that the JWH-018 can provide a therapeutic effect on the pathogenesis of leukemia and particularly upon LSCs and SCs might have therapeutic potential in addition to current therapy. |
